COPD imposes considerable worldwide burden in terms of morbidity and mortality. In
recognition of this, there is now extensive focus on early diagnosis, secondary prevention …

Chronic obstructive pulmonary disease (COPD), a respiratory disease characterized by a
progressive decline in lung function, is considered to be a leading cause of morbidity and …

Preclinical studies suggested that aclidinium and glycopyrronium might have a faster onset
of action than tiotropium. In this study we assessed the onset of action of aclidinium and …

Background The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus
tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific …

US9056100B2 - Quinuclidine derivatives and medicinal compositions containing the same -
Google Patents US9056100B2 - Quinuclidine derivatives and medicinal compositions containing …

Introduction: The fixed dose combinations used in chronic obstructive pulmonary disease
(COPD) patients need their rationale evaluation. If there is no added benefit; then it amounts …

Combination therapy with anticholinergics and β 2-agonists should be used in COPD
patients after failure of previous monotherapy with one of these drugs. Synergistic effect of …

Ghidul GOLD recomandă ca tratament de elecţie bronhodilatatoarele de lungă durată, în
prima linie de tratament, începând din stadiul II şi până în stadiul IV de boală, toate celelalte …

Introduction: The fixed dose combinations used in chronic obstructive pulmonary disease
(COPD) patients need their rationale evaluation. If there is no added benefit; then it amounts …

Aims: To evaluate therapeutic rationality of combining long-acting β2-agonists (formoterol)
with duration of action of 12 hours and anticholinergics (tiotropium) with 24 hours as fixed …